News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
385,046 Results
Type
Article (18708)
Company Profile (289)
Press Release (366049)
Multimedia
Podcasts (51)
Webinars (8)
Section
Business (111610)
Career Advice (432)
Deals (21570)
Drug Delivery (54)
Drug Development (61741)
Employer Resources (52)
FDA (9343)
Job Trends (7639)
News (202368)
Policy (16948)
Tag
Academia (1261)
Accelerated approval (4)
Adcomms (15)
Allergies (68)
Alliances (28557)
ALS (79)
Alzheimer's disease (1104)
Antibody-drug conjugate (ADC) (111)
Approvals (9363)
Artificial intelligence (183)
Autoimmune disease (22)
Automation (8)
Bankruptcy (199)
Best Places to Work (6779)
BIOSECURE Act (7)
Biosimilars (52)
Biotechnology (238)
Bladder cancer (72)
Brain cancer (23)
Breast cancer (214)
Cancer (1855)
Cardiovascular disease (146)
Career advice (378)
Career pathing (5)
CAR-T (141)
Cell therapy (385)
Cervical cancer (15)
Clinical research (50750)
Collaboration (671)
Compensation (309)
Complete response letters (18)
COVID-19 (1415)
CRISPR (45)
C-suite (194)
Cystic fibrosis (91)
Data (1975)
Denatured (12)
Depression (40)
Diabetes (199)
Diagnostics (3092)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (18)
Drug discovery (98)
Drug pricing (63)
Drug shortages (17)
Duchenne muscular dystrophy (95)
Earnings (48093)
Editorial (30)
Employer branding (5)
Employer resources (46)
Events (62596)
Executive appointments (543)
FDA (10415)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (605)
Gene editing (106)
Generative AI (15)
Gene therapy (284)
GLP-1 (460)
Government (1960)
Grass and pollen (3)
Guidances (126)
Healthcare (9840)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (107)
Indications (24)
Infectious disease (1512)
Inflammatory bowel disease (129)
Inflation Reduction Act (10)
Influenza (32)
Intellectual property (83)
Interviews (61)
IPO (11501)
IRA (25)
Job creations (1235)
Job search strategy (335)
Kidney cancer (8)
Labor market (13)
Layoffs (238)
Leadership (7)
Legal (2939)
Liver cancer (52)
Lung cancer (247)
Lymphoma (121)
Machine learning (7)
Management (12)
Manufacturing (200)
MASH (63)
Medical device (6274)
Medtech (6276)
Mergers & acquisitions (10581)
Metabolic disorders (530)
Multiple sclerosis (71)
NASH (14)
Neurodegenerative disease (77)
Neuropsychiatric disorders (26)
Neuroscience (1576)
NextGen: Class of 2025 (2951)
Non-profit (1384)
Now hiring (22)
Obesity (271)
Opinion (145)
Ovarian cancer (74)
Pain (71)
Pancreatic cancer (73)
Parkinson's disease (130)
Partnered (10)
Patents (186)
Patient recruitment (100)
Peanut (40)
People (32096)
Pharmaceutical (50)
Pharmacy benefit managers (12)
Phase I (16950)
Phase II (23057)
Phase III (15870)
Pipeline (1174)
Policy (77)
Postmarket research (1272)
Preclinical (6961)
Press Release (36)
Prostate cancer (86)
Psychedelics (35)
Radiopharmaceuticals (230)
Rare diseases (341)
Real estate (2120)
Recruiting (19)
Regulatory (13560)
Reports (20)
Research institute (1212)
Resumes & cover letters (56)
Rett syndrome (5)
RNA editing (5)
RSV (24)
Schizophrenia (65)
Series A (116)
Series B (75)
Service/supplier (2)
Sickle cell disease (49)
Special edition (12)
Spinal muscular atrophy (124)
Sponsored (23)
Startups (2250)
State (1)
Stomach cancer (8)
Supply chain (40)
Tariffs (16)
The Weekly (38)
Vaccines (325)
Venture capitalists (35)
Weight loss (157)
Women's health (17)
Worklife (5)
Date
Last 7 days (762)
Last 30 days (2251)
Last 365 days (25043)
2025 (8960)
2024 (27026)
2023 (29939)
2022 (36105)
2021 (38010)
2020 (33991)
2019 (23986)
2018 (17734)
2017 (19623)
2016 (17016)
2015 (20742)
2014 (15130)
2013 (11186)
2012 (11462)
2011 (12016)
2010 (11388)
Location
Africa (286)
Alabama (46)
Alaska (3)
Arizona (99)
Arkansas (8)
Asia (26530)
Australia (5689)
California (4989)
Canada (1681)
China (440)
Colorado (193)
Connecticut (222)
Delaware (127)
Europe (51570)
Florida (694)
Georgia (160)
Idaho (21)
Illinois (313)
India (20)
Indiana (170)
Iowa (2)
Japan (132)
Kansas (70)
Kentucky (9)
Louisiana (8)
Maine (45)
Maryland (629)
Massachusetts (3878)
Michigan (97)
Minnesota (220)
Mississippi (1)
Missouri (48)
Montana (18)
Nebraska (9)
Nevada (50)
New Hampshire (49)
New Jersey (1437)
New Mexico (14)
New York (1362)
North Carolina (758)
North Dakota (6)
Northern California (2209)
Ohio (135)
Oklahoma (9)
Oregon (23)
Pennsylvania (1033)
Puerto Rico (9)
Rhode Island (20)
South America (449)
South Carolina (16)
Southern California (1910)
Tennessee (60)
Texas (676)
United States (17926)
Utah (105)
Virginia (112)
Washington D.C. (40)
Washington State (477)
West Virginia (2)
Wisconsin (24)
385,046 Results for "psioxus therapeutics limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
·
3 min read
Press Releases
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
May 2, 2025
·
6 min read
Press Releases
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
May 8, 2025
·
6 min read
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Business
PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer
PsiOxus Therapeutics, Ltd. today announces the appointment of Howard Davis, Ph.D., as Chief Executive Officer.
August 11, 2022
·
5 min read
Layoffs
Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials
Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, Pliant is paring back its workforce.
May 2, 2025
·
2 min read
·
Angela Gabriel
Genetown
Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics
Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced a $30 million convertible note financing co-led by a group of leading US life science investors.
January 5, 2023
·
7 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering
May 6, 2025
·
4 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
April 14, 2025
·
5 min read
Press Releases
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
April 7, 2025
·
4 min read
1 of 38,505
Next
